Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2022,
Myovant Sciences paid$0.0 Mil more to buy back shares than it received from issuing new shares.
It received$0.0 Mil from issuing more debt.
It paid$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received$0.0 Mil from paying cash dividends to shareholders.
It received$0.0 Mil on other financial activities.
In all, Myovant Sciences
spent$0.0 Mil on financial activities for the
three
months ended in Mar. 2022.
Myovant Sciences Cash Flow from Financing Historical Data
The historical data trend for Myovant Sciences's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myovant Sciences Annual Data
Trend
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Cash Flow from Financing
45.65
273.90
145.93
238.05
25.91
Myovant Sciences Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Cash Flow from Financing
32.76
4.14
11.00
4.01
6.76
Myovant Sciences Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Myovant Sciences's Cash from Financing for the fiscal year that ended in Mar. 2022 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $25.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myovant Sciences (NYSE:MYOV) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Myovant Sciences's issuance of stock for the
three
months ended in Mar. 2022 was $0.0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Myovant Sciences's repurchase of stock for the
three
months ended in Mar. 2022 was $0.0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Myovant Sciences's net issuance of debt for the
three
months ended in Mar. 2022 was $0.0 Mil.
Myovant Sciences received$0.0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Myovant Sciences's net issuance of preferred for the
three
months ended in Mar. 2022 was $0.0 Mil.
Myovant Sciences paid$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Myovant Sciences's cash flow for dividends for the
three
months ended in Mar. 2022 was $0.0 Mil.
Myovant Sciences received$0.0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Myovant Sciences's other financing for the
three
months ended in Mar. 2022 was $0.0 Mil.
Myovant Sciences received$0.0 Mil on other financial activities.
Myovant Sciences Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.51(3.7%) Volume: 712,123 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 
